The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma.

Background: Malignant gliomas have disproportionally high morbidity and mortality. Heterozygous mutations in the isocitrate dehydrogenase 1 (IDH1) gene are most common in glioma, resulting in predominantly arginine to histidine substitution at codon 132. Because IDH1 requires a wild-type allele to produce (D)-2-hydroxyglutarate for epigenetic reprogramming, loss of IDH1 heterozygosity is associated with glioma progression in an IDH1-wildtype-like phenotype.